{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T18:31:08Z","timestamp":1790620268466,"version":"4.1.0"},"reference-count":33,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,3,17]],"date-time":"2025-03-17T00:00:00Z","timestamp":1742169600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Travel Medicine and Infectious Disease"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1016\/j.tmaid.2025.102840","type":"journal-article","created":{"date-parts":[[2025,3,20]],"date-time":"2025-03-20T18:18:19Z","timestamp":1742494699000},"page":"102840","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Operational challenges and lessons learned from conducting febrile surveillance in a long-term randomized dengue vaccine trial in Latin America and Asia-Pacific"],"prefix":"10.1016","volume":"65","author":[{"given":"Harald","family":"Pfaar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eduardo","family":"L\u00f3pez-Medina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ian","family":"Escudero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanee","family":"Hutagalung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas","family":"Roubinis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seloni","family":"Thakrar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charissa Fay","family":"Corazon Borja-Tabora","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vianney","family":"Tricou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suely","family":"Tuboi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.tmaid.2025.102840_bib1","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1038\/nature12060","article-title":"The global distribution and burden of dengue","volume":"496","author":"Bhatt","year":"2013","journal-title":"Nature"},{"key":"10.1016\/j.tmaid.2025.102840_bib3","article-title":"Global epidemiology of dengue hemorrhagic fever: an update","volume":"5","author":"Sanyaolu","year":"2017","journal-title":"J Hum Virol Retrovirol"},{"key":"10.1016\/j.tmaid.2025.102840_bib4","doi-asserted-by":"crossref","first-page":"S7","DOI":"10.1038\/nrmicro2460","article-title":"Dengue: a continuing global threat","volume":"8","author":"Guzman","year":"2010","journal-title":"Nat Rev Microbiol"},{"key":"10.1016\/j.tmaid.2025.102840_bib5","doi-asserted-by":"crossref","first-page":"317","DOI":"10.3389\/fcimb.2017.00317","article-title":"Global epidemiology of dengue outbreaks in 1990\u20132015: a systematic review and meta-analysis","volume":"7","author":"Guo","year":"2017","journal-title":"Front Cell Infect Microbiol"},{"key":"10.1016\/j.tmaid.2025.102840_bib6","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1086\/315215","article-title":"Dengue viremia titer, antibody response pattern, and virus serotype correlate with disease severity","volume":"181","author":"Vaughn","year":"2000","journal-title":"J Infect Dis"},{"key":"10.1016\/j.tmaid.2025.102840_bib12","doi-asserted-by":"crossref","DOI":"10.1016\/j.virusres.2022.199018","article-title":"Dengue virus infection\u2013a review of pathogenesis, vaccines, diagnosis and therapy","volume":"324","author":"Kok","year":"2023","journal-title":"Virus Res"},{"key":"10.1016\/j.tmaid.2025.102840_bib13","doi-asserted-by":"crossref","first-page":"2575","DOI":"10.3390\/v14112575","article-title":"Immune-mediated pathogenesis in dengue virus infection","volume":"14","author":"Khanam","year":"2022","journal-title":"Viruses"},{"key":"10.1016\/j.tmaid.2025.102840_bib14","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1093\/infdis\/jiv179","article-title":"Safety and immunogenicity of a live attenuated tetravalent dengue vaccine candidate in flavivirus-naive adults: a randomized, double-blinded phase 1 clinical trial","volume":"212","author":"George","year":"2015","journal-title":"J Infect Dis"},{"key":"10.1016\/j.tmaid.2025.102840_bib15","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1016\/S1473-3099(14)70811-4","article-title":"Safety and immunogenicity of a recombinant live attenuated tetravalent dengue vaccine (DENVax) in flavivirus-naive healthy adults in Colombia: a randomised, placebo-controlled, phase 1 study","volume":"14","author":"Osorio","year":"2014","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.tmaid.2025.102840_bib16","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/S1473-3099(17)30632-1","article-title":"Immunogenicity and safety of one versus two doses of tetravalent dengue vaccine in healthy children aged 2\u201317 years in Asia and Latin America: 18-month interim data from a phase 2, randomised, placebo-controlled study","volume":"18","author":"S\u00e1ez-Llorens","year":"2018","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.tmaid.2025.102840_bib17","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.1093\/infdis\/jiv762","article-title":"Safety and immunogenicity of a tetravalent dengue vaccine candidate in healthy children and adults in dengue-endemic regions: a randomized, placebo-controlled phase 2 study","volume":"213","author":"Sirivichayakul","year":"2016","journal-title":"J Infect Dis"},{"key":"10.1016\/j.tmaid.2025.102840_bib18","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1016\/S0140-6736(20)30556-0","article-title":"Safety and immunogenicity of a tetravalent dengue vaccine in children aged 2\u201317 years: a randomised, placebo-controlled, phase 2 trial","volume":"395","author":"Tricou","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.tmaid.2025.102840_bib19","doi-asserted-by":"crossref","first-page":"e257","DOI":"10.1016\/S2214-109X(23)00522-3","article-title":"Long-term efficacy and safety of a tetravalent dengue vaccine (TAK-003): 4\u00b75-year results from a phase 3, randomised, double-blind, placebo-controlled trial","volume":"12","author":"Tricou","year":"2024","journal-title":"Lancet Global Health"},{"key":"10.1016\/j.tmaid.2025.102840_bib20","doi-asserted-by":"crossref","DOI":"10.1080\/21645515.2023.2254964","article-title":"An open-label, Phase 3 trial of TAK-003, a live attenuated dengue tetravalent vaccine, in healthy US adults: immunogenicity and safety when administered during the second half of a 24-month shelf-life","volume":"19","author":"Patel","year":"2023","journal-title":"Hum Vaccines Immunother"},{"key":"10.1016\/j.tmaid.2025.102840_bib21","doi-asserted-by":"crossref","DOI":"10.1093\/infdis\/jiae222","article-title":"Efficacy and safety of a tetravalent dengue vaccine (TAK-003) in children with prior Japanese encephalitis or yellow fever vaccination","author":"Sirivichayakul","year":"2024","journal-title":"J Infect Dis"},{"key":"10.1016\/j.tmaid.2025.102840_bib23","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/S0140-6736(24)00046-1","article-title":"Brazil to start widespread dengue vaccinations","volume":"403","author":"Alves","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.tmaid.2025.102840_bib24","doi-asserted-by":"crossref","first-page":"2009","DOI":"10.1056\/NEJMoa1903869","article-title":"Efficacy of a tetravalent dengue vaccine in healthy children and adolescents","volume":"381","author":"Biswal","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.tmaid.2025.102840_bib25","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1093\/infdis\/jiaa761","article-title":"Efficacy of a dengue vaccine candidate (TAK-003) in healthy children and adolescents 2 years after vaccination","volume":"225","author":"L\u00f3pez-Medina","year":"2022","journal-title":"J Infect Dis"},{"key":"10.1016\/j.tmaid.2025.102840_bib26","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1093\/cid\/ciab864","article-title":"Three-year efficacy and safety of Takeda's dengue vaccine candidate (TAK-003)","volume":"75","author":"Rivera","year":"2022","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.tmaid.2025.102840_bib27","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1016\/S0140-6736(20)30414-1","article-title":"Efficacy of a tetravalent dengue vaccine in healthy children aged 4\u201316 years: a randomised, placebo-controlled, phase 3 trial","volume":"395","author":"Biswal","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.tmaid.2025.102840_bib30","doi-asserted-by":"crossref","first-page":"14688","DOI":"10.1073\/pnas.1508114112","article-title":"Asymptomatic humans transmit dengue virus to mosquitoes","volume":"112","author":"Duong","year":"2015","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.tmaid.2025.102840_bib31","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1056\/NEJMra1110265","article-title":"Dengue","volume":"366","author":"Simmons","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.tmaid.2025.102840_bib34","doi-asserted-by":"crossref","first-page":"924","DOI":"10.4161\/hv.23405","article-title":"Challenges and impact of conducting vaccine trials in Asia and Africa: new technologies in emerging markets, October 16th-18th 2012; World Vaccine Congress, Lyon","volume":"9","author":"Kochhar","year":"2013","journal-title":"Hum Vaccines Immunother"},{"key":"10.1016\/j.tmaid.2025.102840_bib35","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1038\/s41577-019-0123-x","article-title":"Adaptive immune responses to primary and secondary dengue virus infections","volume":"19","author":"St John","year":"2019","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.tmaid.2025.102840_bib36","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1016\/S0140-6736(14)61060-6","article-title":"Clinical efficacy and safety of a novel tetravalent dengue vaccine in healthy children in Asia: a phase 3, randomised, observer-masked, placebo-controlled trial","volume":"384","author":"Capeding","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.tmaid.2025.102840_bib37","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1056\/NEJMoa1411037","article-title":"Efficacy of a tetravalent dengue vaccine in children in Latin America","volume":"372","author":"Villar","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.tmaid.2025.102840_bib38","doi-asserted-by":"crossref","DOI":"10.1371\/annotation\/ae27d48b-025f-47ce-8427-4af59f821ad7","article-title":"Analytical and clinical performance of the CDC real time RT-PCR assay for detection and typing of dengue virus","volume":"7","author":"Santiago","year":"2013","journal-title":"PLoS Neglected Trop Dis"},{"key":"10.1016\/j.tmaid.2025.102840_bib39","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1056\/NEJMoa2301790","article-title":"Live, attenuated, tetravalent butantan\u2013dengue vaccine in children and adults","volume":"390","author":"Kall\u00e1s","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.tmaid.2025.102840_bib41","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2021-056086","article-title":"Early impact of the COVID-19 pandemic on in-person outpatient care utilisation: a rapid review","volume":"12","author":"Dupraz","year":"2022","journal-title":"BMJ Open"},{"key":"10.1016\/j.tmaid.2025.102840_bib42","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2020-045343","article-title":"Impact of COVID-19 pandemic on utilisation of healthcare services: a systematic review","volume":"11","author":"Moynihan","year":"2021","journal-title":"BMJ Open"},{"key":"10.1016\/j.tmaid.2025.102840_bib43","doi-asserted-by":"crossref","DOI":"10.3390\/ijerph191710768","article-title":"Dengue infections during COVID-19 period: reflection of reality or elusive data due to effect of pandemic","volume":"19","author":"Khan","year":"2022","journal-title":"Int J Environ Res Publ Health"},{"key":"10.1016\/j.tmaid.2025.102840_bib45","doi-asserted-by":"crossref","first-page":"64","DOI":"10.4103\/picr.PICR_206_19","article-title":"Recruitment and retention of the participants in clinical trials: challenges and solutions","volume":"11","author":"Chaudhari","year":"2020","journal-title":"Perspect Clin Res"},{"key":"10.1016\/j.tmaid.2025.102840_bib46","doi-asserted-by":"crossref","first-page":"3","DOI":"10.4103\/picr.picr_161_21","article-title":"Strategies for participant retention in long term clinical trials: a participant\u2013centric approaches","volume":"14","author":"Poongothai","year":"2023","journal-title":"Perspect Clin Res"}],"container-title":["Travel Medicine and Infectious Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1477893925000468?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1477893925000468?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T20:35:38Z","timestamp":1762547738000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1477893925000468"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5]]},"references-count":33,"alternative-id":["S1477893925000468"],"URL":"https:\/\/doi.org\/10.1016\/j.tmaid.2025.102840","relation":{},"ISSN":["1477-8939"],"issn-type":[{"value":"1477-8939","type":"print"}],"subject":[],"published":{"date-parts":[[2025,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Operational challenges and lessons learned from conducting febrile surveillance in a long-term randomized dengue vaccine trial in Latin America and Asia-Pacific","name":"articletitle","label":"Article Title"},{"value":"Travel Medicine and Infectious Disease","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.tmaid.2025.102840","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Takeda Vaccines, Inc. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"102840"}}